The introduction of MAFLD has brought about a notable transformation in liver disease classification by incorporating metabolic abnormality indicators, such as insulin resistance, heightened sensitivity to C-reactive protein (CRP), and other complex metabolic risk factors [1,2]. This evidence concerns the gene CRP and liver disorder.